title: Invasive pneumococcal disease in HIV-infected adults in France from 2000 to 2011: antimicrobial susceptibility and implication of serotypes for vaccination.
abstract: OBJECTIVE
  Invasive pneumococcal diseases (IPD) remain frequent and severe events in human immunodeficiency virus (HIV)-infected subjects despite the use of antiretroviral therapy and the availability of vaccines. Our aim was to assess the antibiotic susceptibilities and serotypes of strains responsible for IPD in HIV-infected patients.
  
  
  METHODS
  We retrospectively analyzed all Streptococcus pneumoniae strains isolated from normally sterile sites between 2000 and 2011 in HIV-infected patients from a single reference center in Paris. The minimum inhibitory concentrations were determined by the E-test, and serotyping was performed by the antiserum agglutination method.
  
  
  RESULTS
  Among our study group, 41 HIV-infected adults presented 43 IPD during the study period. Of these 41 patients, 78 % were men, and the median age was 43 (range 23-62) years. the median CD4 cell count was 184/mm(3) (6-1,090/mm(3)), 51 % were receiving antiretroviral therapy, and 24 % had plasma HIV-RNA levels of <400 copies/mL. Only two patients had received the pneumococcal polysaccharide 23-valent vaccine (PPV23). Isolates were susceptible to penicillin G, amoxicillin, and cotrimoxazole in 44, 70, and 59 % of cases, respectively, and were significantly less susceptible to these antibiotics than isolates in the French general population during the same period. Among the 27 strains serotyped, 18 different serotypes were observed, of which 19A, 14, 7F, and 6A were the most frequent. Serotype distribution was similar to that in the French general population. The PPV23 vaccine and the 13-valent conjugate vaccine (PCV13) would have theoretically covered 78 and 70 % of cases, respectively.
  
  
  CONCLUSIONS
  In our HIV-infected patient cohort, S. pneumoniae isolates demonstrated higher levels of resistance to beta-lactamines and cotrimoxazole than in the French general population. HIV-infected patients should benefit from the herd protection effect expected from the large-scale vaccination of children by PCV13.
authors: Infectious Diseases Department, St Louis Hospital, Assistance-Publique-Hôpitaux de Paris (APHP), 1, Avenue Claude Vellefaux, 75010, Paris, France. annelise.munier@gmail.com
authors: A-L
authors: AL
authors: Munier
authors: V
authors: V
authors: de Lastours
authors: E
authors: E
authors: Varon
authors: J-L
authors: JL
authors: Donay
authors: R
authors: R
authors: Porcher
authors: J-M
authors: JM
authors: Molina
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D016470:Bacteremia / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D005260:Female; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008297:Male; D016920:Meningitis, Bacterial / Q000453:epidemiology / Q000382:microbiology / Q000517:prevention & control; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D011008:Pneumococcal Infections / Q000453:epidemiology* / Q000382:microbiology* / Q000517:prevention & control; D022242:Pneumococcal Vaccines / Q000008:administration & dosage / Q000276:immunology; D012189:Retrospective Studies; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000145:classification* / Q000187:drug effects* / Q000276:immunology / Q000302:isolation & purification; D014611:Vaccination / Q000379:methods; D055815:Young Adult
chemical_list: C538862:13-valent pneumococcal vaccine; D000900:Anti-Bacterial Agents; D022242:Pneumococcal Vaccines
references: N Engl J Med. 2010 Mar 4;362(9):812-22
references: 20200385
references: Lancet Infect Dis. 2005 Feb;5(2):83-93
references: 15680778
references: Microb Drug Resist. 2011 Mar;17(1):31-6
references: 20809835
references: Ann Intern Med. 2006 Jan 3;144(1):1-9
references: 16389249
references: J Infect Dis. 1997 Apr;175(4):975-8
references: 9086163
references: J Infect Dis. 2002 May 1;185(9):1364-8
references: 12001059
references: AIDS. 2012 Jan 2;26(1):87-94
references: 22008657
references: J Infect Dis. 2005 Aug 1;192(3):377-86
references: 15995950
references: AIDS. 2007 Nov 30;21(18):2425-34
references: 18025879
references: Clin Infect Dis. 2005 Oct 1;41(7):930-8
references: 16142656
references: N Engl J Med. 2003 Oct 2;349(14):1341-8
references: 14523142
references: N Engl J Med. 2006 Apr 6;354(14):1522-4
references: 16598050
references: HIV Med. 2009 Sep;10(8):488-95
references: 19459987
references: BMC Infect Dis. 2007 Oct 23;7:119
references: 17956620
references: Clin Infect Dis. 2001 Mar 1;32(5):794-800
references: 11229848
references: Arch Intern Med. 2005 Jul 11;165(13):1533-40
references: 16009870
references: Clin Infect Dis. 2004 Jun 1;38(11):1623-8
references: 15156452
references: J Infect Dis. 2004 Aug 15;190(4):707-12
references: 15272398
references: Ann Intern Med. 1989 Jul 15;111(2):133-42
references: 2545125
references: Med Mal Infect. 2010 Dec;40(12):683-90
references: 20822870
references: AIDS. 2006 Feb 14;20(3):437-44
references: 16439878
references: MMWR Morb Mortal Wkly Rep. 2012 Oct 12;61(40):816-9
references: 23051612
references: HIV Med. 2011 Jul;12(6):323-33
references: 21059168
references: J Infect Dis. 2007 Nov 1;196(9):1346-54
references: 17922399
references: Lancet. 1995 Oct 14;346(8981):1034-5
references: 7475565
references: Clin Infect Dis. 2007 Oct 1;45(7):e82-7
references: 17806042
references: Clin Infect Dis. 2008 Dec 1;47(11):1388-95
references: 18959493
references: CMAJ. 2009 Jan 6;180(1):48-58
references: 19124790
references: Clin Infect Dis. 1996 Mar;22(3):437-40
references: 8852959
references: Lancet. 2000 Jun 17;355(9221):2106-11
references: 10902624
references: Vaccine. 2010 Nov 10;28(48):7583-8
references: 20887830